Skip to main content
Premium Trial:

Request an Annual Quote

Arrowhead Inks Peptide Delivery Tech Deal with Shire

Premium

Arrowhead Research and Shire this week announced that they have struck an alliance to develop and commercialize drugs combining Arrowhead's targeted delivery peptides and Shire's therapeutic payloads.

Arrowhead acquired the peptide technology in April through its $2.1 million all-stock acquisition of Alvos Therapeutics (GSN 4/12/2012).

Under the deal, Arrowhead will identify peptides that selectively bind and internalize in an undisclosed tissue type, permitting drug delivery.

Arrowhead stands to receive research funding, as well as development, regulatory, and commercialization milestones of up to $32.8 million for each drug candidate, plus royalties. Shire will have the option to exclusively license the candidates and would assume full responsibility for their development and marketing.

Additional terms were not disclosed.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more